Aptevo Therapeutics Inc. filed a Form S-1 registration statement with the Securities and Exchange Commission on November 20, 2026, to register up to 13,888,890 shares of common stock issuable upon exercise of inducement warrants for resale by certain selling stockholders.

Key Highlights

  • Shares registered: Up to 13,888,890 shares of common stock, par value $0.001 per share, issuable upon exercise of Inducement Warrants.
  • Inducement Warrant exercise price: $1.08 per share, according to the filing.
  • Warrant issuance date: The Inducement Warrants were issued pursuant to Warrant Inducement and Reload Letters dated November 11, 2026.
  • Exercisability condition: The filing states the Inducement Warrants "are not exercisable until we obtain the required stockholder approval."
  • Last reported sale price: On November 19, 2026, the last reported sale price of common stock on the Nasdaq Capital Market was $0.41 per share.
  • Proceeds to company: The filing states the company "will not receive any of the proceeds from the sale of the Resale Shares by the Selling Stockholders."
  • Registration costs: The company disclosed it will bear all costs, expenses, and fees in connection with the registration of the Resale Shares.

Aptevo Registers Inducement Warrant Shares at $1.08 Exercise Price

Aptevo Therapeutics Inc. (NASDAQ:APVO), a Delaware-incorporated company headquartered at 2401 4th Avenue, Suite 1050, Seattle, Washington, filed a Form S-1 registration statement on November 20, 2026. The filing registers up to 13,888,890 shares of common stock issuable upon exercise of common stock purchase warrants described in the prospectus as "Inducement Warrants." According to the filing, these warrants were issued to certain holders of the company's existing warrants pursuant to Warrant Inducement and Reload Letters dated November 11, 2026.

The registration is structured as a resale shelf offering under Rule 415 of the Securities Act of 1933. The selling stockholders named in the prospectus may resell or dispose of the shares from time to time through underwriters, broker-dealers, agents, or other means described in the filing's "Plan of Distribution" section. The filing specifies that the Inducement Warrants carry an exercise price of $1.08 per share and are not exercisable until the company obtains required stockholder approval. As of November 19, 2026, the last reported sale price of Aptevo's common stock on the Nasdaq Capital Market was $0.41 per share.

The filing notes that the company will not receive proceeds from the selling stockholders' resale of shares, though it would receive proceeds if and when the Inducement Warrants are exercised directly. The company will bear all costs, expenses, and fees associated with the registration. The prospectus identifies Jeffrey G. Lamothe as President and Chief Executive Officer, and SoYoung Kwon as Senior Vice President and General Counsel. The company is classified in the filing as a non-accelerated filer and a smaller reporting company.

What Was Disclosed

Aptevo Therapeutics filed a Form S-1 on November 20, 2026, to register 13,888,890 shares underlying Inducement Warrants priced at $1.08 per share, issued November 11, 2026, for resale by selling stockholders. Exercisability is contingent on stockholder approval.